7,351 Shares in Evolent Health, Inc. (NYSE:EVH) Bought by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC purchased a new stake in shares of Evolent Health, Inc. (NYSE:EVH) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 7,351 shares of the technology company’s stock, valued at approximately $228,000.

Several other hedge funds have also bought and sold shares of EVH. Signaturefd LLC boosted its stake in shares of Evolent Health by 1,470.7% in the fourth quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock worth $48,000 after acquiring an additional 1,353 shares during the period. NBC Securities Inc. purchased a new stake in shares of Evolent Health in the fourth quarter worth about $69,000. Strs Ohio lifted its position in shares of Evolent Health by 46.3% in the fourth quarter. Strs Ohio now owns 6,000 shares of the technology company’s stock worth $198,000 after buying an additional 1,900 shares in the last quarter. Johnson Investment Counsel Inc. purchased a new stake in Evolent Health during the fourth quarter valued at approximately $209,000. Finally, Xponance Inc. purchased a new stake in Evolent Health during the fourth quarter valued at approximately $222,000.

Evolent Health Stock Performance

Shares of EVH stock opened at $22.07 on Wednesday. The stock has a market cap of $2.56 billion, a PE ratio of -17.66 and a beta of 1.44. The business has a 50-day simple moving average of $25.41 and a 200-day simple moving average of $29.35. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a 52-week low of $20.54 and a 52-week high of $35.00.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, May 9th. The technology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.04. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. The firm had revenue of $639.65 million during the quarter, compared to analyst estimates of $601.60 million. On average, equities analysts expect that Evolent Health, Inc. will post 0.9 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on EVH. JMP Securities decreased their price target on Evolent Health from $38.00 to $34.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. JPMorgan Chase & Co. cut their price target on Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, March 15th. Canaccord Genuity Group cut their price target on Evolent Health from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Citigroup began coverage on Evolent Health in a research note on Monday, April 22nd. They set a “buy” rating and a $40.00 target price on the stock. Finally, Oppenheimer assumed coverage on Evolent Health in a research note on Friday, March 1st. They set an “outperform” rating and a $45.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Evolent Health has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.